$ACRV

$1.72 -$0.01 (0.58%) Close

$ACRV Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 42.9M shares outstanding

Who owns ACRV?

By type of holder

Institutions 49.9% Insiders 23.6% Everyone else 26.5%

Concentration Top 10 holders own 129.0%

Peter Kolchinsky 28.7% · Rajeev Shah 28.7%

Institutional ownership

49.9%

+12.0 pts vs last qtr

Institutional holders

+2 vs last qtr

Net shares bought

+5.2M

by institutions in Q2 2026

New / sold out

6 / 4

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Ra Capital Management, L.P. +3.9M
Acadian Asset Management LLC +319.1K

Biggest sellers in Q2 2026

Jane Street Group, LLC −165.0K
Panagora Asset Management Inc SOLD OUT −33.8K

Who is planning to sell?

Notices of proposed sale, last 12 months

$30.6K

1 notice from 1 person

Shares covered

14.0K

0.03% of the company

Arranged in advance

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Peter Blume-Jensen Officer $30.6K

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2022–FY2025

+834.3%

+110.61% a year

Each share's claim on the business

−89.3%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $42.8M

over 4 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years83% 1–3 years10% Under 1 year7%

Quarterly turnover

17.8%

of institutional shares changed hands

Top 10 managers, median time held

3.3 years

Super Investors

Investment managers reporting ACRV on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
RC Ra Capital Management, L.P. 13D · 28.8%	12.2M	28.54%	+3.9M (+46.6%)	2022	0.2%
Shares held by quarter Peak holding12.2M (Q2'26) Change over 8 quarters+3.9M Share of the company28.540% Disclosed stake13D · 28.8% Ra Capital Management, L.P.'s full portfolio →
SC Sands Capital Alternatives, LLC	2.3M	5.34%	+166.7K (+7.9%)	2022	0.7%
Shares held by quarter Peak holding2.3M (Q2'26) Change over 8 quarters+166.7K Share of the company5.340% Sands Capital Alternatives, LLC's full portfolio →

Ra Capital Management, L.P.

13D · 28.8%

12.2M

% of company

28.54%

Change vs last qtr

+3.9M (+46.6%)

Held since

2022

Sands Capital Alternatives, LLC

2.3M

% of company

5.34%

Change vs last qtr

+166.7K (+7.9%)

Held since

2022

27 more super investors behind a free account

See every manager holding Acrivon Therapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ACRV on Form N-PORT; together they hold 3.4% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$971K	545.5K	1.27%	0.00%	June 30, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$693K	389.6K	0.91%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$971K

% of company

1.27%

% of the fund

0.00%

As of

June 30, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$693K

% of company

0.91%

% of the fund

0.00%

As of

June 30, 2026

11 more funds behind a free account

See every fund holding Acrivon Therapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
PK Peter Kolchinsky 5%+ holder 13D · 28.8%	12.3M	28.67%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company28.670% Disclosed stake13D · 28.8% View the 13D/G filing →
RS Rajeev Shah 5%+ holder 13D · 28.8%	12.3M	28.67%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company28.670% Disclosed stake13D · 28.8% View the 13D/G filing →

Peter Kolchinsky

5%+ holder13D · 28.8%

12.3M

% of company

28.67%

Change vs last qtr

—

Held since

—

Rajeev Shah

5%+ holder13D · 28.8%

12.3M

% of company

28.67%

Change vs last qtr

—

Held since

—

15 more holders behind a free account

See every insider and 5%+ holder of Acrivon Therapeutics, Inc..

Comments